206 related articles for article (PubMed ID: 10428900)
1. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine.
de Muys JM; Gourdeau H; Nguyen-Ba N; Taylor DL; Ahmed PS; Mansour T; Locas C; Richard N; Wainberg MA; Rando RF
Antimicrob Agents Chemother; 1999 Aug; 43(8):1835-44. PubMed ID: 10428900
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
3. Selection and characterization of HIV-1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine (dOTC).
Richar N; Quan Y; Salomon H; Hsu M; Bedard J; Harrigan PR; Rando R; Mansour T; Bowlin TL; Wainberg MA
Antivir Ther; 1999; 4(3):171-7. PubMed ID: 12731757
[TBL] [Abstract][Full Text] [Related]
4. Resistance profiles of (+)2'-deoxy-3'-oxa-4'-thiocytidine and (-)2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.
Richard N; Salomon H; Oliveira M; Rando R; Wainberg MA
Nucleosides Nucleotides; 1999; 18(4-5):773-8. PubMed ID: 10432679
[TBL] [Abstract][Full Text] [Related]
5. Absolute bioavailability and disposition of (-) and (+) 2'-deoxy- 3'-oxa-4'-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humans.
Smith PF; Forrest A; Ballow CH; Martin DE; Proulx L
Antimicrob Agents Chemother; 2000 Jun; 44(6):1609-15. PubMed ID: 10817717
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice.
Stoddart CA; Moreno ME; Linquist-Stepps VD; Bare C; Bogan MR; Gobbi A; Buckheit RW; Bedard J; Rando RF; McCune JM
Antimicrob Agents Chemother; 2000 Mar; 44(3):783-6. PubMed ID: 10681360
[TBL] [Abstract][Full Text] [Related]
7. Selection of resistance-conferring mutations in HIV-1 by the nucleoside reverse transcriptase inhibitors (+/-)dOTC and (+/-)dOTFC.
Richard N; Salomon H; Oliveira M; Rando R; Mansour T; Gu Z; Wainberg MA
Antivir Chem Chemother; 2000 Nov; 11(6):359-65. PubMed ID: 11227993
[TBL] [Abstract][Full Text] [Related]
8. Virologic and enzymatic studies revealing the mechanism of K65R- and Q151M-associated HIV-1 drug resistance towards emtricitabine and lamivudine.
Feng JY; Myrick FT; Margot NA; Mulamba GB; Rimsky L; Borroto-Esoda K; Selmi B; Canard B
Nucleosides Nucleotides Nucleic Acids; 2006; 25(1):89-107. PubMed ID: 16440988
[TBL] [Abstract][Full Text] [Related]
9. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside analogs that target HIV-1 reverse transcriptase.
Anderson KS
Biochim Biophys Acta; 2002 Jul; 1587(2-3):296-9. PubMed ID: 12084471
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, and pharmacokinetics of single oral doses of BCH-10652 in healthy adult males.
Smith PF; Forrest A; Ballow CH; Martin DE; Proulx L
Antimicrob Agents Chemother; 2000 Oct; 44(10):2816-23. PubMed ID: 10991865
[TBL] [Abstract][Full Text] [Related]
11. Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
Nakata H; Amano M; Koh Y; Kodama E; Yang G; Bailey CM; Kohgo S; Hayakawa H; Matsuoka M; Anderson KS; Cheng YC; Mitsuya H
Antimicrob Agents Chemother; 2007 Aug; 51(8):2701-8. PubMed ID: 17548498
[TBL] [Abstract][Full Text] [Related]
12. In vitro interactions between apricitabine and other deoxycytidine analogues.
Bethell R; De Muys J; Lippens J; Richard A; Hamelin B; Ren C; Collins P
Antimicrob Agents Chemother; 2007 Aug; 51(8):2948-53. PubMed ID: 17517847
[TBL] [Abstract][Full Text] [Related]
13. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
Periclou AP; Nandy P; Avramis VI
In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
Gu Z; Wainberg MA; Nguyen-Ba N; L'Heureux L; de Muys JM; Bowlin TL; Rando RF
Antimicrob Agents Chemother; 1999 Oct; 43(10):2376-82. PubMed ID: 10508010
[TBL] [Abstract][Full Text] [Related]
16. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
Hernandez-Santiago BI; Mathew JS; Rapp KL; Grier JP; Schinazi RF
Antimicrob Agents Chemother; 2007 Jun; 51(6):2130-5. PubMed ID: 17403996
[TBL] [Abstract][Full Text] [Related]
17. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.
Krebs R; Immendörfer U; Thrall SH; Wöhrl BM; Goody RS
Biochemistry; 1997 Aug; 36(33):10292-300. PubMed ID: 9254628
[TBL] [Abstract][Full Text] [Related]
18. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase.
Feng JY; Murakami E; Zorca SM; Johnson AA; Johnson KA; Schinazi RF; Furman PA; Anderson KS
Antimicrob Agents Chemother; 2004 Apr; 48(4):1300-6. PubMed ID: 15047533
[TBL] [Abstract][Full Text] [Related]
19. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.
Gu Z; Allard B; de Muys JM; Lippens J; Rando RF; Nguyen-Ba N; Ren C; McKenna P; Taylor DL; Bethell RC
Antimicrob Agents Chemother; 2006 Feb; 50(2):625-31. PubMed ID: 16436719
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.
Dutschman GE; Bridges EG; Liu SH; Gullen E; Guo X; Kukhanova M; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1799-804. PubMed ID: 9661024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
